Trending Topics in Gastroenterology | GastroAGI

The hepatitis B vaccine—the first anti-cancer vaccine (Lancet Gastro Hepato 2026)

The hepatitis B vaccine, often hailed as the first anti-cancer vaccine, represents a groundbreaking achievement in global public health. Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), a deadly form of liver cancer. By preventing HBV infection, the vaccine directly reduces the risk of HCC, making it a powerful tool in cancer prevention. Since its introduction, the hepatitis B vaccine has significantly reduced HBV infection rates worldwide, particularly in regions with historically high prevalence, such as Southeast Asia. This region has long borne the brunt of HBV-related diseases, with millions suffering from chronic infections and liver-related complications. Universal vaccination programs, especially those targeting newborns and infants, have been instrumental in curbing HBV transmission from mother to child, one of the primary modes of infection. The vaccine's impact is profound—countries with high vaccination coverage have reported dramatic declines in HBV prevalence and HCC incidence among younger generations. For example, in Taiwan, a pioneer in HBV vaccination, the incidence of childhood HCC has nearly been eradicated. As global vaccination efforts expand, the hepatitis B vaccine continues to save millions of lives, offering hope for a future free from HBV and its devastating consequences, including liver cancer.

Rat Hepatitis E - J of Hepatology-Jan.26

Rat Hepatitis E (rHEV), also known as Rocahepevirus ratti, is an emerging zoonotic pathogen that has garnered significant attention in recent years due to its potential to infect humans and cause clinical disease. It was first identified in wild rats in Germany in 2009 and has since been detected in rodents and other small mammals across the globe. Although it was initially believed to be confined to rodents, subsequent studies have revealed its zoonotic potential, with confirmed human cases reported in multiple countries. ### Differences Between Rat Hepatitis E (rHEV) and Human Hepatitis E (HEV) Human Hepatitis E is primarily caused by the Paslahepevirus balayani genus, which includes genotypes HEV-1 to HEV-4. In contrast, Rat Hepatitis E belongs to the Rocahepevirus genus. While both viruses share structural similarities, including a ~7 kb positive-sense single-stranded RNA genome organized into four open reading frames (ORFs), they differ significantly in genetic composition. rHEV shares only about 50–60% nucleotide identity with human HEV, making it genetically distinct. Key differences include: 1. **Host Range**: - Human HEV (HEV-1 to HEV-4) primarily infects humans, pigs, and other animals. - rHEV was initially thought to be rodent-specific but has now been shown to infect humans as well, indicating its zoonotic potential. 2. **Genomic Differences**: - Despite structural similarities, rHEV exhibits significant genetic divergence from human HEV, particularly in nucleotide sequences. 3. **Diagnostic Challenges**: - Routine hepatitis E diagnostics often fail to detect rHEV infections, as they are designed for Paslahepevirus. Diagnosis of rHEV requires specialized pan-hepevirus PCR assays, highlighting the limitations of current diagnostic methods. 4. **Clinical Presentation**: - Human HEV infections can cause a spectrum of disease ranging from asymptomatic to severe acute hepatitis, particularly in pregnant women and immunocompromised individuals. - rHEV infections in humans have also shown a wide range of clinical manifestations, from asymptomatic cases to severe acute and chronic hepatitis. Extrahepatic complications, such as acute renal failure, glomerulonephritis, acute pancreatitis, and meningoencephalitis, have also been reported. ### Clinical Impact of Rat Hepatitis E The emergence of rHEV as a zoonotic pathogen raises several important clinical and public health concerns: 1. **Human Cases**: - Since the first human case of rHEV was identified in 2017 in a liver transplant recipient in Hong Kong, a total of 48 human infections have been reported across Hong Kong, Spain, mainland China, France, Germany, and Canada. These cases involved individuals of both sexes and a wide age range (7–89 years). 2. **Chronic Hepatitis**: - Chronic hepatitis, which can potentially progress to cirrhosis, has been observed in immunocompromised individuals infected with rHEV. In the Hong Kong cohort, 12 out of 22 identified cases developed chronic hepatitis. 3. **Treatment**: - No virus-specific therapies are currently available for rHEV. However, ribavirin, a drug commonly used to treat human HEV infections, has shown efficacy in some rHEV cases. 4. **Extrahepatic Manifestations**: - rHEV infections have been associated with severe complications beyond the liver, including acute renal failure, glomerulonephritis, acute pancreatitis, and meningoencephalitis. 5. **Global Circulation**: - Phylogenetic analyses suggest that rHEV strains are circulating globally, likely facilitated by the movement of rodents or contaminated materials. Strains from a single geographic region do not always form monophyletic groups, indicating ongoing global transmission. ### Future Clinical and Public Health Implications 1. **Zoonotic Risk**: - rHEV's ability to infect humans without requiring major genetic changes underscores its zoonotic potential. Broader genomic surveillance in both human and animal populations is essential to better understand transmission routes and zoonotic risks. 2. **Diagnostic Improvements**: - Incorporating rHEV-specific assays into routine diagnostic protocols for unexplained hepatitis is critical to identifying and managing cases. This approach has already proven effective in Hong Kong, where 22 human cases were identified over seven years. 3. **Evolutionary Insights**: - Molecular clock analyses suggest that rHEV originated a few hundred years ago, with some strains circulating in rodents and potentially humans for decades before being recognized. Understanding its evolutionary history can help distinguish between newly emerging threats and long-standing but overlooked pathogens. 4. **Molecular Adaptation**: - Studies indicate that rHEV is well-adapted to human hosts, with codon usage patterns and selective pressures suggesting that most rHEV lineages possess the translational capacity to replicate efficiently in human cells. Ongoing research is needed to identify molecular adaptations that facilitate cross-species transmission. 5. **Surveillance and Public Health Strategies**: - Expanding genomic surveillance and developing standardized classification systems, such as the open-access tool created by researchers, will enable better tracking of rHEV strains and their public health impact. Enhanced surveillance will also help identify genetic determinants of human adaptation and monitor the emergence of new strains. 6. **Infection Prevention**: - As rodents are the primary reservoir for rHEV, controlling rodent populations and minimizing human exposure to contaminated environments are crucial for preventing infections. ### Conclusion Rat Hepatitis E (rHEV) is an emerging zoonotic pathogen with significant clinical and public health implications. While it shares some similarities with human HEV, its genetic distinctiveness and zoonotic potential make it a unique public health concern. The identification of human cases, particularly in immunocompromised individuals, highlights the need for improved diagnostic tools, expanded surveillance, and further research into its transmission dynamics and molecular adaptations. Understanding the full extent of rHEV's impact will be critical for anticipating future risks and developing effective prevention and treatment strategies.

HBsAg, HBeAg and HCC prediction

HBsAg (Hepatitis B surface antigen) and HBeAg (Hepatitis B e antigen) are important biomarkers in understanding the progression and risk factors of chronic hepatitis B virus (HBV) infection, particularly in relation to hepatocellular carcinoma (HCC) prediction. ### HBeAg and HCC Risk: HBeAg status is a key indicator of the phase of chronic HBV infection. HBeAg-positive patients generally have higher HBV DNA levels and an increased risk of HCC compared to HBeAg-negative patients. However, the relationship between HBV DNA levels and HCC risk differs based on HBeAg status: - For **HBeAg-negative patients**, HCC risk increases with higher HBV DNA levels, plateauing at ≥5 log10 IU/mL. - For **HBeAg-positive patients**, the association between HBV DNA levels and HCC risk is less pronounced. ### HBsAg and HCC Risk: HBsAg levels provide additional insight into HCC risk: - In **HBeAg-negative patients**, high HBsAg levels (≥1000 IU/mL) are associated with increased HCC risk. - In **HBeAg-positive patients**, a reverse association is observed. High HBsAg levels (≥10,000 IU/mL) are linked to a lower risk of HCC, particularly in the immune-tolerant phase. ### Immune-Tolerant Phase and HCC: Patients in the immune-tolerant phase (defined by HBeAg positivity, high HBV DNA, normal ALT, and no significant fibrosis) generally have a low short-term HCC risk. However, HCC risk increases over time due to factors like aging, phase transitions, or declining HBsAg levels. Long-term monitoring is essential, as a drop in HBsAg levels or a phase transition significantly elevates HCC risk. ### Clinical Implications: - Patients with HBeAg positivity and HBsAg levels ≥10,000 IU/mL are considered genuinely immune-tolerant and have a lower HCC risk. Those with lower HBsAg levels (<10,000 IU/mL) may have a higher risk and require closer monitoring or antiviral treatment. - Dynamic monitoring, rather than relying solely on baseline characteristics, is crucial to account for the fluctuating nature of chronic HBV infection. Factors like age, fibrosis, family history of HCC, and metabolic conditions (e.g., diabetes) should also inform risk stratification and treatment decisions. In summary, HBsAg and HBeAg levels, along with other clinical factors, play a critical role in predicting HCC risk and guiding management strategies for patients with chronic HBV.

Large-Scale Profiling of HBsAg Levels in Chronic Hepatitis B for Functional Cure Development

The large-scale profiling of hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B (CHB) is a critical area of research aimed at advancing the development of therapies for achieving a functional cure. This study focused on quantitative hepatitis B surface antigen (qHBsAg) profiles, which serve as a key biomarker for understanding viral transcriptional activity and immune control in CHB patients. ### Key Findings: 1. **Baseline qHBsAg Levels**: - Most patients with CHB exhibited relatively low qHBsAg levels at baseline, indicating limited viral activity and some degree of immune control. - However, a significant proportion of patients had persistently high qHBsAg levels, suggesting ongoing viral replication and insufficient immune-mediated control. 2. **Longitudinal Trends**: - qHBsAg levels generally declined very slowly over time, reflecting the indolent nature of antigen loss during chronic infection. - Only a minority of patients achieved HBsAg seroclearance (complete loss of the surface antigen) during long-term follow-up, highlighting the challenges in achieving spontaneous functional cure. 3. **Clinical Predictors of HBsAg Seroclearance**: - Certain factors were associated with lower qHBsAg levels and a greater likelihood of seroclearance: - Older age. - Absence of hepatitis B e antigen (HBeAg). - Lower levels of viral replication. - Higher alanine aminotransferase (ALT) levels relative to qHBsAg levels, which may indicate immune activity against the virus. ### Implications for Functional Cure Development: - **Challenges in Achieving Functional Cure**: - Many CHB patients have qHBsAg profiles that make spontaneous functional cure unlikely. This includes patients with high antigen burdens, who are less likely to respond to current or emerging antiviral treatments. - The slow decline in qHBsAg levels over time underscores the need for therapies that can accelerate antigen loss and improve immune control. - **Stratification of Patients**: - qHBsAg levels can be used to stratify patients based on their likelihood of achieving seroclearance and their responsiveness to treatment. This biomarker provides valuable insights for tailoring therapeutic approaches. - **Drug Development Considerations**: - The study emphasizes the importance of accounting for baseline qHBsAg heterogeneity when designing novel therapies. Patients with high antigen burdens may require more potent or combination therapies to achieve functional cure. - Emerging antiviral strategies should focus on targeting persistent viral activity and enhancing immune-mediated control in patients with high qHBsAg levels. ### Conclusion: This research underscores the importance of large-scale profiling of qHBsAg levels in CHB patients to better understand the dynamics of antigen loss and to inform the development of more effective therapies. By identifying clinical predictors of seroclearance and highlighting the challenges posed by high antigen burdens, the study provides a roadmap for advancing therapeutic strategies aimed at achieving a functional cure for CHB.

STASH Trial

The **STASH trial** (Short for "Steroid Tapering in Severe Alcohol-associated Hepatitis") was a multicenter, open-label randomized clinical trial aimed at evaluating the efficacy and safety of a tapered prednisolone regimen compared to the standard fixed-dose regimen in patients with **severe alcohol-associated hepatitis (AAH)**. The trial was conducted to address concerns about the high risk of infections associated with corticosteroid treatment in AAH patients, while still preserving its therapeutic benefits. ### Background: Severe AAH is a life-threatening condition characterized by liver inflammation due to excessive alcohol consumption. Corticosteroids, such as prednisolone, are the standard treatment for severe AAH because they reduce liver inflammation and improve short-term survival. However, corticosteroids suppress the immune system, leading to a high risk of **secondary infections**, which can worsen patient outcomes. Clinical guidelines recommend a fixed daily dose of **40 mg prednisolone for 28 days**, but there has been ongoing debate about whether a tapering regimen could reduce infection risks while maintaining efficacy. ### Study Design: - **Study Period**: March 2023 to August 2024. - **Participants**: 254 adults diagnosed with severe AAH. - **Intervention Groups**: 1. **Fixed-dose group**: Participants received 40 mg/day of prednisolone for 28 days (standard regimen). 2. **Tapered-dose group**: Participants received a four-week tapering regimen of prednisolone (gradual dose reduction over 28 days). - **Primary Endpoint**: Incidence of infections by day 90, assessed using standardized criteria. - **Secondary Endpoints**: Mortality at day 90, transplant-free survival, liver function improvement (measured by MELD score), rates of acute kidney injury (AKI), and overall adverse events. ### Key Findings: 1. **Infection Risk**: - Tapered-dose group had significantly fewer infections by day 90 compared to the fixed-dose group (**19.7% vs. 33.1%**). - Microbiologically confirmed infections were also reduced in the tapered-dose group. - The most common infections were lung infections, followed by urinary and peritoneal infections. 2. **Mortality and Survival**: - Despite the reduction in infection rates, there was **no significant difference in day-90 mortality** or transplant-free survival between the two groups. 3. **Liver Function and AKI**: - Both groups showed similar improvements in liver function (MELD score) and comparable rates of acute kidney injury. 4. **Adverse Events**: - Overall adverse events and hospitalizations were more frequent in the fixed-dose group, suggesting a safety advantage with the tapering regimen. ### Conclusion: The STASH trial demonstrated that a **tapered prednisolone regimen significantly reduces the risk of infections** in patients with severe AAH compared to the standard fixed-dose regimen. Importantly, this reduction in infection risk was achieved **without compromising short-term survival** or liver function improvement. These findings suggest that tapering corticosteroids is a safer and more effective strategy for managing severe AAH, addressing the long-standing challenge of balancing immunosuppression with infection risk. ### Implications: The results of the STASH trial could lead to a revision of current clinical guidelines for the treatment of severe AAH, favoring a tapered prednisolone regimen over the fixed-dose approach. This approach may improve patient safety and outcomes by minimizing secondary infections, which are a major cause of morbidity and mortality in this population.

Zetomipzomib and the PORTOLA Trial

Zetomipzomib and the PORTOLA Trial represent a significant advancement in the treatment of autoimmune hepatitis (AIH), particularly for patients who are inadequately controlled on standard therapies like steroids and azathioprine. Below is a detailed explanation of both Zetomipzomib and the PORTOLA trial: ### **Zetomipzomib (KZR-616):** Zetomipzomib is a groundbreaking, first-in-class selective immunoproteasome inhibitor. Unlike conventional proteasome inhibitors typically used in oncology, zetomipzomib specifically targets the immunoproteasome subunits **LMP7** and **LMP2**. These subunits are primarily active in immune cells, such as activated T cells, B cells, and antigen-presenting cells, which are crucial players in autoimmune diseases like AIH. #### **Mechanism of Action:** By selectively inhibiting the immunoproteasome, zetomipzomib works in the following ways: 1. **Reduces presentation of autoantigens:** This limits the immune system's ability to attack self-tissues. 2. **Downregulates pathogenic Th1/Th17 responses:** These responses are known to drive inflammation and tissue damage in autoimmune diseases. 3. **Restores regulatory immune balance:** It promotes immune homeostasis without causing broad immunosuppression, which minimizes the risk of infections and other complications associated with traditional immunosuppressive therapies. This mechanism positions zetomipzomib as a promising alternative to conventional therapies, potentially reducing the toxicities and side effects associated with steroids and azathioprine. --- ### **The PORTOLA Phase 2a Trial:** The PORTOLA trial is the first clinical study to evaluate zetomipzomib in patients with autoimmune hepatitis who have not responded adequately to standard therapy. This trial is a critical step in understanding the drug's efficacy and safety in this difficult-to-treat patient population. #### **Key Features of the PORTOLA Trial:** 1. **Open-label, multi-center design:** The trial involves multiple research centers and does not use a placebo control, allowing all participants to receive zetomipzomib. 2. **Subcutaneous weekly dosing:** Zetomipzomib is administered via weekly subcutaneous injections, which is a convenient and patient-friendly approach. 3. **Inclusion criteria:** The trial specifically targets patients with persistent elevations in liver enzymes (ALT/AST) despite ongoing immunosuppressive therapy. --- ### **Emerging Clinical Outcomes:** Preliminary results from the PORTOLA trial (expected to be fully presented in 2024–2025) demonstrate significant promise for zetomipzomib in AIH management: 1. **Improvements in liver enzyme levels:** Many patients experienced meaningful reductions in ALT and AST levels, indicating improved liver function. 2. **Reduction in IgG levels:** Elevated IgG is a hallmark of AIH, and its reduction suggests a decrease in disease activity. 3. **Steroid-sparing effects:** Several patients were able to reduce their steroid requirements while maintaining or improving disease control. 4. **Biochemical remission or near-remission:** Some patients achieved biochemical remission or near-remission, even while tapering conventional immunosuppressive drugs. 5. **Tolerability:** Zetomipzomib was generally well-tolerated, with mild adverse effects such as fatigue, injection-site reactions, and transient gastrointestinal symptoms. These findings suggest that zetomipzomib could address unmet needs in AIH, particularly for patients who experience disease flares or side effects from current therapies. --- ### **Why This Matters for AIH:** Autoimmune hepatitis is a chronic condition that often requires long-term immunosuppression, with many patients experiencing treatment challenges due to side effects or incomplete responses to standard drugs. Zetomipzomib offers a novel, targeted approach to modulating the immune system, addressing the core pathophysiology of the disease. If larger studies confirm the PORTOLA trial's findings, zetomipzomib could become: 1. **A steroid-sparing option:** Reducing the reliance on corticosteroids and their associated toxicities. 2. **A therapy for incomplete responders:** Providing a solution for patients whose disease remains active despite standard treatments. 3. **A mechanistically novel treatment:** As the first major innovation in AIH pharmacotherapy in decades, zetomipzomib could redefine how the disease is managed. Overall, zetomipzomib and the PORTOLA trial represent a promising step forward in improving outcomes for patients with autoimmune hepatitis, particularly those with difficult-to-treat disease.

Redefining PSC Care

Redefining care for Primary Sclerosing Cholangitis (PSC) requires a comprehensive, patient-centered approach that integrates modern strategies for symptom management, disease progression monitoring, and quality-of-life improvements. PSC is a chronic liver disease with significant unmet needs, including severe symptoms, high cancer risks, and limited therapeutic options. Below is a detailed breakdown of how PSC care is being redefined: ### 1. **Symptom Management: Addressing Quality-of-Life Concerns** - **Pruritus (Itching):** Pruritus is one of the most common and debilitating symptoms of PSC, affecting about 50% of patients, with 30% experiencing moderate-to-severe itching. Despite the widespread use of treatments like bile acid sequestrants (36%), hydroxyzine (23%), rifampicin (17%), and naltrexone (14%), many of these therapies have limited efficacy. - **Call for Better Therapies:** There is an urgent need for safe, effective, and long-term antipruritic medications. The FITCH trial demonstrated promising results with bezafibrate, which improved pruritus by at least 50% in 41% of patients compared to 11% in the placebo group. - **Patient Priorities:** Symptom relief, particularly pruritus, is a top motivator for patients joining drug trials, highlighting the importance of addressing quality-of-life symptoms in care strategies. ### 2. **Structured Surveillance and Monitoring** - **Scheduled ERCP Follow-Up:** Regularly scheduled ERCP (endoscopic retrograde cholangiopancreatography) interventions have been shown to improve long-term transplant-free survival and reduce infections compared to on-demand procedures. The low complication rate (4%) ensures safety when the procedure is performed in a structured, protocolized manner. - **Routine MRCP Surveillance:** Magnetic resonance cholangiopancreatography (MRCP) allows earlier detection of dominant strictures and cholangiocarcinoma, which leads to better survival outcomes. Routine MRCP reduces the risk of death by 73.8% compared to symptom-triggered imaging (HR 0.9, p < 0.001). This proactive approach identifies disease progression earlier and enables timely interventions. - **Stricture-Driven Management:** The benefits of MRCP surveillance come from proactive management of biliary strictures rather than relying solely on late detection of hepatic malignancies. ### 3. **Patient Involvement in Research** - **Engagement Gap:** While 61% of patients are willing to participate in clinical trials, only 26% have been asked, highlighting a significant gap in patient engagement and recruitment. - **Patient Motivation:** Pruritus relief is the top motivator for PSC patients joining drug trials, emphasizing the need for trials focused on quality-of-life improvements and symptom control. - **Future Directions:** Greater inclusion of patient-reported outcome measures in research and therapeutic development is essential for personalized care. ### 4. **Cancer Screening and Risk Management** - **High Cancer Risk:** PSC remains a progressive disease with a high risk for hepatobiliary and colorectal cancers. Surveillance strategies like MRCP and ERCP are critical for early detection of cholangiocarcinoma and dominant strictures. - **Earlier Detection Advantage:** Routine imaging allows for timely interventions that improve survival outcomes. ### 5. **Modern Therapeutic Development** - **Personalized Care:** Future PSC care will emphasize personalized, high-quality ambulatory hepatology care tailored to individual patient needs. - **ABCDE Model:** A stepwise PSC care strategy includes: - **A**wareness: Educating patients about PSC and its risks. - **B**ile ducts: Monitoring and managing strictures and infections. - **C**ancer: Screening for hepatobiliary and colorectal cancers. - **D**isability: Addressing quality-of-life symptoms like pruritus and fatigue. - **E**xplore trials: Encouraging participation in clinical trials to advance treatment options. ### 6. **Improved Disease Management** - **Long-Term ERCP Follow-Up:** Regular ERCP interventions help identify disease progression earlier and reduce recurrent cholangitis episodes, improving transplant-free survival. - **State-of-the-Art Review Findings:** Modern care strategies focus on halting disease progression and improving life quality through symptom control, structured surveillance, and personalized treatment approaches. ### 7. **Conclusion: Redefining PSC Care** Redefining PSC care involves combining early symptom-focused interventions, structured surveillance (MRCP/ERCP), and personalized treatment approaches. This integrated strategy targets both halting disease progression and improving patient quality of life. The urgent need for effective antipruritic therapies, better patient engagement in research, and proactive cancer screening further underscores the importance of modernizing PSC care. By addressing unmet needs and leveraging advancements in monitoring and therapeutic development, PSC care can significantly improve long-term outcomes and provide patients with a better quality of life.

Treatment of Chronic Hepatitis B - AASLD/IDSA Guideline 2025

As of my knowledge cutoff in October 2023, the most recent guidelines for the treatment of chronic hepatitis B (CHB) were published by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). While I cannot provide details on a "2025 guideline," I can summarize the key recommendations from the most recent guidance available, which may still be relevant in 2025 unless updated guidelines have been released. ### Key Recommendations from the AASLD Guidelines for CHB Management #### 1. **Phases of Chronic Hepatitis B** - Chronic hepatitis B is categorized into five disease phases: 1. *Immune-tolerant phase*: High HBV DNA levels, normal ALT, minimal liver damage. 2. *Immune-active phase (HBeAg-positive or HBeAg-negative)*: Elevated ALT, active liver inflammation, and high HBV DNA. 3. *Inactive carrier phase*: Low HBV DNA, normal ALT, minimal liver inflammation. 4. *HBsAg-negative clearance phase*: HBsAg loss with anti-HBs development. 5. *Indeterminate phase*: Patients who do not clearly fit into the above phases. - Management strategies are tailored to the patient’s disease phase, ALT levels, HBV DNA levels, and liver fibrosis status. #### 2. **Preferred Antiviral Therapies** - First-line oral antiviral agents include: - **Entecavir (ETV)** - **Tenofovir disoproxil fumarate (TDF)** - **Tenofovir alafenamide (TAF)** - These drugs are highly effective and have a high barrier to resistance, making them the preferred choices for long-term HBV suppression. #### 3. **Treatment for Specific Populations** - **Immune-Tolerant Phase**: - Antiviral therapy is recommended for patients over 40 years old or those with significant liver inflammation or fibrosis (≥F2). - **Indeterminate Phase**: - Treatment decisions should be individualized for HBeAg-negative patients without cirrhosis who fall into the "grey zone" of unclear disease activity. Shared decision-making is emphasized. - **Pregnancy**: - For HBsAg-positive pregnant women with HBV DNA >200,000 IU/mL, initiate TDF or TAF at 28 weeks of gestation to prevent mother-to-child transmission. - **Breastfeeding**: - TDF and TAF are considered safe during breastfeeding due to minimal drug transfer into breast milk. #### 4. **Antiviral Discontinuation** - Nucleos(t)ide analog (NA) therapy should not be stopped unless HBsAg loss (functional cure) is achieved, as discontinuation otherwise poses a risk of HBV relapse or flare. - If therapy is discontinued, close monitoring of ALT and HBV DNA levels is required every 1–3 months for the first 6 months, then quarterly for the next year. #### 5. **Functional Cure** - The ultimate goal of therapy is achieving HBsAg loss (functional cure). However, this outcome is rare with current therapies and is more commonly achieved with interferon-based treatments than with nucleos(t)ide analogs. #### 6. **Fibrosis Assessment** - Non-invasive tools such as transient elastography (FibroScan) and FIB-4 are recommended for evaluating liver fibrosis and determining the need for treatment. #### 7. **Surveillance for Hepatocellular Carcinoma (HCC)** - High-risk groups require lifelong HCC surveillance with semiannual ultrasound ± alpha-fetoprotein (AFP) testing. These groups include: - Patients with cirrhosis. - Males over 40 years and females over 50 years. - Patients with a family history of HCC. - Patients co-infected with HBV and HIV or hepatitis D virus (HDV). #### 8. **Prevention of HBV Transmission** - Antiviral therapy should be considered for HBsAg-positive individuals at high risk of transmitting HBV (e.g., healthcare workers, sexual partners). - Universal HBV vaccination is recommended for all adults aged 19–59 years and all infants. #### 9. **HBV-HIV and HBV-HDV Coinfection** - Patients co-infected with HBV and HDV or HIV should undergo regular HCC surveillance regardless of their liver fibrosis status. #### 10. **Research Gaps and Future Directions** - The AASLD has identified key research priorities, including: - Developing better biomarkers for disease activity and treatment response (e.g., HBsAg quantitation, HBcrAg, HBV RNA). - Exploring new strategies for achieving a functional cure. - Addressing management of patients in the indeterminate phase. - Future updates to the guidelines are planned as new therapies and diagnostic tools are approved by the FDA. #### 11. **Shared Decision-Making** - Patient preferences, ability to adhere to treatment, and access to therapy should guide decisions on initiating, continuing, or discontinuing treatment. #### 12. **Alignment with WHO Goals** - The AASLD supports the World Health Organization’s (WHO) initiative to simplify HBV treatment criteria, but retains phase-based thresholds for high-resource settings. --- ### Conclusion The AASLD/IDSA guidelines emphasize individualized care, evidence-based recommendations, and shared decision-making in the management of chronic hepatitis B. First-line antiviral therapies (ETV, TDF, TAF) are effective for long-term viral suppression, and treatment strategies are tailored to the patient’s disease phase, age, and comorbidities. Prevention of HBV transmission, including vaccination and antiviral prophylaxis in high-risk populations, remains a cornerstone of public health efforts. Ongoing research and future updates will likely focus on achieving functional cures and improving diagnostic and treatment approaches. If you are specifically looking for the 2025 guideline, I recommend checking the AASLD or IDSA websites for the latest updates and publications.

Secondary Iron Overload and the Liver

Secondary iron overload is more common than hereditary hemochromatosis and arises from conditions such as transfusions, ineffective erythropoiesis, and chronic liver diseases. Iron absorption is regulated by hepcidin, which suppresses ferroportin when iron levels are high, reducing plasma iron entry. Diagnosing iron overload involves assessing transferrin saturation (TSAT >45%) and ferritin levels, though ferritin can be elevated due to inflammation or malignancy. Non-invasive imaging, particularly MRI, is preferred for measuring liver iron content, as it correlates well with biopsy results. Secondary iron overload is linked to various conditions, including iron-loading anemias (e.g., thalassemia, myelodysplastic syndromes, sickle cell disease) and chronic liver diseases (e.g., non-alcoholic fatty liver disease [NAFLD], alcoholic liver disease [ALD], viral hepatitis). Thalassemia is a leading cause due to frequent transfusions and suppressed hepcidin, with risks of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD and ALD are also associated with iron overload, contributing to worse outcomes and advanced fibrosis. Hepatitis C virus (HCV) suppresses hepcidin, increasing iron absorption, while hepatitis B virus (HBV) with HDV co-infection correlates with advanced fibrosis. Treatment depends on the cause: phlebotomy for hereditary hemochromatosis and post-transplant cases without anemia, and iron chelators for transfusion-dependent conditions like thalassemia. No proven therapies currently exist for NAFLD-, hepatitis-, or ALD-related iron overload.

Cardiac Syndromes in Liver Disease

Cardiac syndromes in liver disease encompass a spectrum of complex interactions between the heart and liver, with both organs mutually influencing each other. These syndromes include congestive hepatopathy (CH), cardiogenic liver injury (CLI), cirrhotic cardiomyopathy (CCM), hepatopulmonary syndrome (HPS), and portopulmonary hypertension (PoPH). Below is a detailed explanation of these syndromes and their management: --- ### 1. **Congestive Hepatopathy (CH)** #### **Pathophysiology**: - CH occurs due to **long-standing venous congestion** from chronic heart failure, affecting 15–65% of heart-failure patients. - Mechanisms include **backward transmission of right-atrial pressure**, **cholestasis**, **microthrombi**, and **hypoxic injury**, which contribute to hepatic fibrosis. #### **Clinical Presentation**: - CH is often **asymptomatic**, with mild elevation of liver enzymes (AST/ALT <3× upper limit) and cholestatic patterns. - **Ascites** may develop in ~25% of patients. #### **Management**: - Focuses on **optimizing heart function**: - **Diuretics** to manage fluid overload. - **Treatment of tricuspid regurgitation**. - **Sacubitril/valsartan** to improve heart failure outcomes. - Prognostic tools like **MELD-XI scores** and hepatic fibrosis scores are used in heart-failure and transplant candidates. --- ### 2. **Cardiogenic Liver Injury (CLI)** #### **Pathophysiology**: - CLI is an **acute liver injury** caused by **sudden hypoperfusion** combined with **venous stasis**, occurring in 20–30% of acute heart-failure cases. #### **Clinical Presentation**: - **Dramatic lab changes**: - AST/ALT and LDH levels rise >20× within days. - ALT/LDH ratio <1.5 strongly suggests **hypoxic hepatitis**. #### **Management**: - Immediate correction of **cardiac/respiratory failure**. - Use of **norepinephrine** for shock and **dobutamine** for inotropy. - Early mechanical support (e.g., ECMO or ventricular assist devices) when needed. #### **Prognosis**: - CLI has a **serious prognosis**, with high mortality risk even after enzyme normalization. - Worse outcomes are associated with **encephalopathy** or **high phosphate levels**. --- ### 3. **Cirrhotic Cardiomyopathy (CCM)** #### **Pathophysiology**: - CCM is a **cardiac dysfunction** specific to cirrhosis, occurring despite the absence of prior heart disease. Prevalence ranges from 26–81%. - Mechanisms include **hyperdynamic circulation**, **inflammation**, **autonomic dysfunction**, and **myocardial remodeling**. #### **Diagnostic Criteria** (Updated in 2020): - **Systolic dysfunction**: LVEF ≤50% or GLS <18%. - **Diastolic dysfunction**: ≥3 echocardiographic abnormalities (e.g., E/A ratio, deceleration time, E/e′ ratio). #### **Management**: - Evidence is limited; management focuses on: - **Volume control** with diuretics. - **Natriuretic-dose spironolactone**. - **Cautious use of beta-blockers**. - **Sodium restriction**. --- ### 4. **Hepatopulmonary Syndrome (HPS)** #### **Pathophysiology**: - HPS occurs in ~25% of cirrhotic patients and is defined by **liver disease**, **intrapulmonary vasodilation**, and **hypoxemia**. #### **Diagnosis**: - Confirmed through **contrast-enhanced transthoracic echocardiography (CE-TTE)**, showing delayed microbubble appearance. - **PaO2 <70 mmHg** with widened alveolar–arterial (A–a) gradient supports the diagnosis. #### **Management**: - No effective medical therapy exists. - **Oxygen supplementation** for PaO2 <60 mmHg. - **Liver transplantation (LT)** is the only curative option. --- ### 5. **Portopulmonary Hypertension (PoPH)** #### **Pathophysiology**: - PoPH occurs in ~2–6% of patients with portal hypertension. - It requires **right-heart catheterization** for definitive diagnosis. #### **Management**: - Based on **pulmonary arterial hypertension (PAH) therapies**: - **Endothelin receptor antagonists (ERA)**. - **Phosphodiesterase-5 (PDE-5) inhibitors**. - **Prostacyclin analogs**. - **Macitentan** showed improvement in pulmonary vascular resistance (PVR) in the **PORTICO trial**. --- ### 6. **Atrial Fibrillation (AF) and Liver Disease** #### **Management Considerations**: - **Non-vitamin K antagonist oral anticoagulants (NOACs)** are preferred over warfarin in **Child-Pugh A/B** patients. - Avoid NOACs in **Child-Pugh class C** due to high bleeding risk. - Individualized decision-making is essential. --- ### Summary Cardiac syndromes in liver disease represent a challenging interplay between cardiac and hepatic dysfunction. These conditions require careful diagnosis and management, as they often have overlapping symptoms and mechanisms. Optimizing heart function, addressing liver-specific complications, and considering transplantation are key strategies in improving outcomes. Detailed prognostic tools, advanced imaging, and targeted therapies are critical for managing these complex syndromes effectively.